Eli Lilly & CO Form 4 insider transactions

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported significant sales of common stock totaling 293,951 shares on November 3, 2025.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 301,342 common shares for approximately $260.7 million on October 31, 2025.

Eli Lilly & Co. Director Gabrielle Sulzberger acquired 6.129 shares of common stock by deferring cash compensation, increasing her beneficial ownership to 2,728.14 shares.

Eli Lilly & Co. Director Juan R. Luciano acquired 18.336 shares of common stock through a deferred compensation plan.

Eli Lilly Director Mary Lynne Hedley increased her direct beneficial ownership by acquiring 12.259 shares of common stock through a compensation deferral plan.

Eli Lilly & Co. Director J. Erik Fyrwald acquired 12.259 shares of common stock, deferring cash compensation into stock units under the Lilly Directors' Deferral Plan.

Eli Lilly & Co. Director Ralph Alvarez acquired 14.525 shares of common stock by deferring cash compensation under the company's Directors' Deferral Plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 3,658 shares of common stock for approximately $3.15 million under a Rule 10b5-1 plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 10,602 shares of common stock on October 9, 2025, for a total value exceeding $9 million.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported multiple sales of common stock totaling 101,420 shares on October 8, 2025, reducing its direct beneficial ownership to 94,547,580 shares.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 26,795 shares of common stock for approximately $22.7 million, executed under a 10b5-1 plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported selling 161,183 shares of common stock for approximately $137 million on October 6, 2025.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, reported the sale of 192,961 shares of common stock for approximately $161 million on October 3, 2025, under a 10b5-1 plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold 112,596 shares of common stock for approximately $92.4 million on October 2, 2025, under a Rule 10b5-1 plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 205,782 shares of common stock on October 1, 2025, as part of a larger series of transactions.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 134,393 shares of common stock on October 1, 2025, under a pre-arranged 10b5-1 trading plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 113,694 shares of common stock for approximately $86.8 million on September 30, 2025.

Lilly Endowment Inc., a 10% owner and director of Eli Lilly & Co., reported the planned sale of 23,665 shares of common stock for approximately $18.06 million under a Rule 10b5-1 plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported selling 106,626 shares of common stock for approximately $81.5 million on September 18, 2025.

Eli Lilly & Co. Director Gabrielle Sulzberger acquired 6.627 shares of common stock by deferring cash compensation, increasing her beneficial ownership to 2,721.97 shares.

Eli Lilly Director Juan R. Luciano acquired 19.826 shares of common stock by deferring cash compensation, increasing his beneficial ownership to 16,455.857 shares.

Eli Lilly director Mary Lynne Hedley acquired 13.254 shares of common stock by deferring cash compensation, increasing her direct beneficial ownership to 2,003.492 shares.

Eli Lilly Director J. Erik Fyrwald acquired 13.254 shares of common stock, deferring them as stock units under the company's deferral plan.

Eli Lilly & Co. Director Ralph Alvarez acquired 15.705 shares of common stock, deferring cash compensation into stock units under a company plan.

Eli Lilly's EVP & President of Manufacturing Operations, Edgardo Hernandez, reported gifting 17 shares of common stock.

Eli Lilly & Co. EVP Kenneth Custer reallocated 612.937 phantom stock units within his deferred compensation account, valued at $734.17 per unit.

Eli Lilly's SVP of Finance and CAO, Donald A. Zakrowski, sold 1,000 shares of common stock for $734.93 per share under a pre-arranged 10b5-1 trading plan.

Eli Lilly & Co. Director Gabrielle Sulzberger acquired 7.103 common stock units at $698.05 per unit as part of a deferred compensation plan.

Eli Lilly & Co. Director Juan R. Luciano acquired 21.25 shares of common stock through a deferred compensation plan.

Eli Lilly & Co. Director Mary Lynne Hedley acquired 14.206 shares of common stock through a compensation deferral plan.